Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023 09 12; 7(17):4748-4759.
View in:
PubMed
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J Clin Oncol. 2023 Jul 11; JCO2300435.
View in:
PubMed
Report on the PET/CT Image-Based Radiation Dosimetry of [18F]FDHT in Women, a Validated Imaging Agent with New Applications for Evaluation of Androgen Receptor Status in Women with Metastatic Breast Cancer. J Nucl Med Technol. 2023 Sep; 51(3):204-210.
View in:
PubMed
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. J Nucl Med. 2023 09; 64(9):1417-1423.
View in:
PubMed
COVID-19: Findings in nuclear medicine from head to toe. Clin Imaging. 2023 Jul; 99:10-18.
View in:
PubMed
SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023 02; 64(2):204-210.
View in:
PubMed
Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges. J Nucl Med. 2023 03; 64(3):349-350.
View in:
PubMed
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma. Hemasphere. 2023 Feb; 7(2):e826.
View in:
PubMed
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging. 2023 04; 50(5):1466-1486.
View in:
PubMed
Interim FDG-PET/CT for Response Assessment of Lymphoma. Semin Nucl Med. 2023 05; 53(3):371-388.
View in:
PubMed
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2022 Nov; 22(11):1163-1175.
View in:
PubMed
Higher SUVmax on FDG-PET is associated with shorter survival in adrenocortical carcinoma. Am J Surg. 2023 02; 225(2):309-314.
View in:
PubMed
Key Factors to Attract More U.S. Diagnostic Radiology Residents into the Field of Nuclear Medicine and Molecular Imaging: A National Survey. Acad Radiol. 2023 04; 30(4):755-762.
View in:
PubMed
177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2022 09; 50(3):203-204.
View in:
PubMed
177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy. J Nucl Med Technol. 2022 09; 50(3):213-214.
View in:
PubMed
Standard Adult Gastric Emptying Scintigraphy Criteria Is Applicable for Partial Meal Ingestion. Dig Dis Sci. 2023 02; 68(2):541-553.
View in:
PubMed
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2022 09 01; 29(9):533-544.
View in:
PubMed
Imaging for Radiation Planning in Breast Cancer. Semin Nucl Med. 2022 09; 52(5):542-550.
View in:
PubMed
Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. Sci Adv. 2022 Apr 29; 8(17):eabl6339.
View in:
PubMed
Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? J Clin Oncol. 2022 09 10; 40(26):3011-3014.
View in:
PubMed
Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers. JAMA Otolaryngol Head Neck Surg. 2022 Mar 01; 148(3):268-276.
View in:
PubMed
Radiation Recall Pneumonitis on FDG PET/CT Triggered by COVID-19 Vaccination. Clin Nucl Med. 2022 Mar 01; 47(3):e281-e283.
View in:
PubMed
Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. J Nucl Med. 2021 Dec; 62(Suppl 3):60S-72S.
View in:
PubMed
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. J Nucl Med. 2021 Dec; 62(Suppl 3):23S-35S.
View in:
PubMed
MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer. Acad Radiol. 2022 05; 29(5):637-647.
View in:
PubMed
PET Imaging for Hematologic Malignancies. Radiol Clin North Am. 2021 Sep; 59(5):705-723.
View in:
PubMed
Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer. Am J Clin Oncol. 2021 09 01; 44(9):449-455.
View in:
PubMed
Evidence-Based Best Practices: 18F-FDG PET Staging of Newly Diagnosed Breast Cancer. Clin Nucl Med. 2021 07 01; 46(7):569-570.
View in:
PubMed
Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms. Ann Nucl Med. 2021 Sep; 35(9):1066-1077.
View in:
PubMed
Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels. Cancers (Basel). 2021 Jun 06; 13(11).
View in:
PubMed
Imaging Androgen Receptors in Breast Cancer with 18F-Fluoro-5a-Dihydrotestosterone PET: A Pilot Study. J Nucl Med. 2022 01; 63(1):22-28.
View in:
PubMed
Intercostal Brown Adipose Tissue on FDG PET/CT. AJR Am J Roentgenol. 2021 10; 217(4):1007.
View in:
PubMed
FDG PET for Assessment of Autologous Stem Cell Transplantation. Semin Nucl Med. 2021 07; 51(4):380-391.
View in:
PubMed
2020 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. J Nucl Med. 2020 10; 61(10):17N-23N.
View in:
PubMed
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
View in:
PubMed
ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. Am J Clin Oncol. 2020 08; 43(8):539-544.
View in:
PubMed
Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning. Breast Cancer Res Treat. 2020 Jun; 181(2):383-390.
View in:
PubMed
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020 03 10; 4(5):858-867.
View in:
PubMed
Extraprostatic Uptake of 18F-Fluciclovine: Differentiation of Nonprostatic Neoplasms From Metastatic Prostate Cancer. AJR Am J Roentgenol. 2020 03; 214(3):641-648.
View in:
PubMed
Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator. Clin Imaging. 2020 02; 59(2):100-103.
View in:
PubMed
2019 SNMMI Highlights Lecture: General Nuclear Medicine and Molecular Imaging. J Nucl Med. 2019 Oct; 60(10):13N-18N.
View in:
PubMed
Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience. Breast J. 2020 03; 26(3):384-390.
View in:
PubMed
No delayed imaging or CCK administration is needed in most cases when bowel excretion does not occur but gallbladder fills promptly. Ann Nucl Med. 2019 Oct; 33(10):740-745.
View in:
PubMed
Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. Eur J Cancer. 2019 06; 114:107-116.
View in:
PubMed
Extraosseous Colonic Uptake of 99mTc-MDP Associated With Iodinated Contrast CT. Clin Nucl Med. 2019 May; 44(5):414-416.
View in:
PubMed
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610.
View in:
PubMed
Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade. Clin Breast Cancer. 2019 04; 19(2):146-155.
View in:
PubMed
2018 SNMMI Highlights Lecture: General Nuclear Medicine. J Nucl Med. 2018 Oct; 59(10):7N-13N.
View in:
PubMed
177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med Technol. 2018 Sep; 46(3):245-246.
View in:
PubMed
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. J Nucl Med Technol. 2018 Sep; 46(3):237-244.
View in:
PubMed
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases. Clin Cancer Res. 2018 09 01; 24(17):4081-4088.
View in:
PubMed
Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice. Nucl Med Commun. 2018 May; 39(5):417-422.
View in:
PubMed
Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations. Clin Genitourin Cancer. 2018 08; 16(4):e919-e926.
View in:
PubMed
PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. Semin Nucl Med. 2018 01; 48(1):37-49.
View in:
PubMed
Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD?×?two cycles followed by FDG-PET/CT restaging and 20?Gy of involved-site radiotherapy. Leuk Lymphoma. 2018 06; 59(6):1384-1390.
View in:
PubMed
Surveillance Imaging in Patients With Endometrial Cancer in First Remission. Curr Probl Diagn Radiol. 2018 Sep; 47(5):311-316.
View in:
PubMed
Initial Experience with Tositumomab and I-131-Labeled Tositumomab for Treatment of Relapsed/Refractory Hodgkin Lymphoma. Mol Imaging Biol. 2017 06; 19(3):429-436.
View in:
PubMed
The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. 2017 Sep; 24(9):2563-2569.
View in:
PubMed
Quantitation of Cancer Treatment Response by 18F-FDG PET/CT: Multicenter Assessment of Measurement Variability. J Nucl Med. 2017 09; 58(9):1429-1434.
View in:
PubMed
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 01 12; 376(2):125-135.
View in:
PubMed
Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood. 2016 11 24; 128(21):2489-2496.
View in:
PubMed
Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. Clin Genitourin Cancer. 2017 04; 15(2):e289-e298.
View in:
PubMed
Cancer Imaging at the Crossroads of Precision Medicine: Perspective From an Academic Imaging Department in a Comprehensive Cancer Center. J Am Coll Radiol. 2016 Apr; 13(4):365-71.
View in:
PubMed
Role of FDG-PET/CT in Extramedullary Multiple Myeloma: Correlation of FDG-PET/CT Findings With Clinical Outcome. Clin Nucl Med. 2016 Jan; 41(1):e7-13.
View in:
PubMed
Systemic Immune Response to Vaccination on FDG-PET/CT. Nucl Med Mol Imaging. 2016 Dec; 50(4):358-361.
View in:
PubMed
Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing. Exp Hematol Oncol. 2015; 4:30.
View in:
PubMed
Inflammatory breast cancer and development of brain metastases: risk factors and outcomes. Breast Cancer Res Treat. 2015 May; 151(1):225-32.
View in:
PubMed
Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management. Ann Surg Oncol. 2015 Aug; 22(8):2483-91.
View in:
PubMed
Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics. 2015 Mar-Apr; 35(2):424-37.
View in:
PubMed
Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma. PET Clin. 2015 Apr; 10(2):207-25.
View in:
PubMed
Radionuclide therapy for osseous metastases in prostate cancer. Semin Nucl Med. 2015 Jan; 45(1):66-80.
View in:
PubMed
Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. Abdom Imaging. 2014 Feb; 39(1):33-9.
View in:
PubMed
Gynecologic oncologic imaging with PET/CT. Semin Nucl Med. 2014; 44(6):461-78.
View in:
PubMed
Postradiation changes in tissues: evaluation by imaging studies with emphasis on fluorodeoxyglucose-PET/computed tomography and correlation with histopathologic findings. PET Clin. 2014 Apr; 9(2):217-35.
View in:
PubMed
What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. Radiographics. 2013 Nov-Dec; 33(7):2003-17.
View in:
PubMed
Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective. AJR Am J Roentgenol. 2013 Oct; 201(4):801-10.
View in:
PubMed
End-therapy positron emission tomography for treatment response assessment in follicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res. 2013 Dec 01; 19(23):6566-77.
View in:
PubMed
Positron emission tomography/computed tomography imaging in Merkel cell carcinoma: a study of 270 scans in 97 patients at the Dana-Farber/Brigham and Women's Cancer Center. J Am Acad Dermatol. 2013 Apr; 68(4):592-599.
View in:
PubMed
PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology. AJR Am J Roentgenol. 2012 Aug; 199(2):W163-7.
View in:
PubMed
PET/CT and renal pathology: a blind spot for radiologists? Part 2--lymphoma, leukemia, and metastatic disease. AJR Am J Roentgenol. 2012 Aug; 199(2):W168-74.
View in:
PubMed
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e647-54.
View in:
PubMed
Molecular imaging training for nuclear medicine residents. J Nucl Med. 2012 Apr; 53(4):655-7.
View in:
PubMed
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 03; 119(18):4129-32.
View in:
PubMed
Molecular imaging training course debuts. J Nucl Med. 2012 Jan; 53(1):16NA.
View in:
PubMed
The relationship between patients' serum glucose levels and metabolically active brown adipose tissue detected by PET/CT. Mol Imaging Biol. 2011 Dec; 13(6):1278-83.
View in:
PubMed
Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL). J Clin Oncol. 2011 May 20; 29(15_suppl):8039.
View in:
PubMed
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer. 2010 Dec; 9(5):297-304.
View in:
PubMed
Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010 Dec; 51(12):1878-84.
View in:
PubMed
Measuring the "unmeasurable": assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol. 2010 Sep; 17(9):1175-85.
View in:
PubMed
Imaging of parathyroid glands. Otolaryngol Clin North Am. 2010 Apr; 43(2):399-415, x.
View in:
PubMed
Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy. J Nucl Med. 2010 Mar; 51(3):368-75.
View in:
PubMed
CT Hounsfield units of brown adipose tissue increase with activation: preclinical and clinical studies. J Nucl Med. 2010 Feb; 51(2):246-50.
View in:
PubMed
Prediction of the need for surgical intervention in obstructive Crohn's disease by 18F-FDG PET/CT. J Nucl Med. 2009 Nov; 50(11):1751-9.
View in:
PubMed
Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy. J Nucl Med. 2009 Nov; 50(11):1760-9.
View in:
PubMed
Limitations of PET/CT in determining need for neck dissection after primary chemoradiation for advanced head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2009; 71(5):251-6.
View in:
PubMed
The importance of brown adipose tissue. N Engl J Med. 2009 Jul 23; 361(4):417-8; author reply 419-20.
View in:
PubMed
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009 May; 50 Suppl 1:122S-50S.
View in:
PubMed
Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies. Med Phys. 2009 May; 36(5):1595-601.
View in:
PubMed
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009 Jun 01; 27(16):2697-704.
View in:
PubMed
Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake. Med Phys. 2009 Feb; 36(2):612-9.
View in:
PubMed
Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab. 2009 Apr; 94(4):1310-6.
View in:
PubMed
18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med. 2009 Jan; 50(1):8-17.
View in:
PubMed
Conversion of FDG PET activity of fibrous dysplasia of the skull late in life mimicking metastatic disease. Clin Nucl Med. 2008 Dec; 33(12):909-11.
View in:
PubMed
Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy. Otolaryngol Clin North Am. 2008 Dec; 41(6):1117-33, viii-ix.
View in:
PubMed
Reproducibility of tumor blood flow quantification with 15O-water PET. J Nucl Med. 2008 Oct; 49(10):1620-7.
View in:
PubMed
Diagnosis and differentiation of bronchioloalveolar carcinoma from adenocarcinoma with bronchioloalveolar components with metabolic and anatomic characteristics using PET/CT. J Nucl Med. 2008 Oct; 49(10):1585-92.
View in:
PubMed
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol. 2008 Sep 01; 26(25):4172-9.
View in:
PubMed
Phase I trial of yttrium 90 ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol. 2008 May 20; 26(15_suppl):8565.
View in:
PubMed
Comparison of residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--Monte Carlo simulation studies. IEEE Trans Med Imaging. 2008 Apr; 27(4):521-30.
View in:
PubMed
Extramedullary hematopoiesis on F-18 FDG PET/CT in a patient with metastatic colon carcinoma. Clin Nucl Med. 2007 Nov; 32(11):878-80.
View in:
PubMed
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov; 48(11):1767-76.
View in:
PubMed
Scalene muscle uptake: a potential pitfall in head and neck PET/CT. Eur J Nucl Med Mol Imaging. 2008 Jan; 35(1):89-94.
View in:
PubMed
Efficacy of preoperative combined 18-fluorodeoxyglucose positron emission tomography and computed tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg. 2007 Aug; 11(8):961-9; discussion 969.
View in:
PubMed
Nuclear medicine training for radiology residents: needs assessment survey. Acad Radiol. 2007 Mar; 14(3):301-5.
View in:
PubMed
Lymphadenopathy resulting from acute hepatitis C infection mimicking metastatic breast carcinoma on FDG PET/CT. Clin Nucl Med. 2006 Jul; 31(7):379-81.
View in:
PubMed
Effects of pegfilgrastim on normal biodistribution of 18F-FDG: preclinical and clinical studies. J Nucl Med. 2006 Jun; 47(6):950-6.
View in:
PubMed
The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2006 Jan; 132(1):12-6.
View in:
PubMed
Combined FDG-positron emission tomography and computed tomography for the detection of ovarian cancer recurrence in an inguinal hernia sac. Gynecol Oncol. 2005 Sep; 98(3):510-2.
View in:
PubMed
Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics. 2005 Jul-Aug; 25(4):1031-43.
View in:
PubMed
F-18 FDG PET/CT in acute respiratory distress syndrome: a case report. Clin Nucl Med. 2004 Dec; 29(12):786-8.
View in:
PubMed
2-Deoxy-2-[18F] fluoro-D-glucose uptake in intercostal respiratory muscles on positron emission tomography/computed tomography: smokers versus nonsmokers. Mol Imaging Biol. 2004 Nov-Dec; 6(6):405-10.
View in:
PubMed